By vgreene, 6 July, 2021 involve multidisciplinary team to discuss risk benefits of cancer prognosis vs HF w pt
By vgreene, 6 July, 2021 pts w interrupted trastuzumab tx or any HER2 targeted molecular tx but w unresolved HF s sx and or LVEF
By vgreene, 6 July, 2021 may resume trastuzumab tx assuming continued HF medical tx ongoing cardiology care
By vgreene, 6 July, 2021 pts w interrupted trastuzumab tx or any HER2 targeted molecular tx w LVEF 40 and or w resolved HF s sx 1
By vgreene, 6 July, 2021 withhold trastuzumab or any HER2 based tx until cardiac status has stabilized involve multidisciplinary team to discuss risks benefits of continuing w pt
By vgreene, 6 July, 2021 pts undergoing trastuzumab tx or any HER2 targeted molecular tx w HF s sx or asymptomatic pts w LVEF
